• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Guardant Health Inc.

    2/20/26 9:05:55 AM ET
    $GH
    Medical Specialities
    Health Care
    Get the next $GH alert in real time by email
    S-8 1 d59825ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on February 20, 2026

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Guardant Health, Inc.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware   45-4139254

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    3100 Hanover Street

    Palo Alto, California

      94304
    (Address of Principal Executive Offices)   (Zip Code)

    2018 Incentive Award Plan

    2018 Employee Stock Purchase Plan

    (Full Title of the Plan)

    John Saia

    Chief Legal Officer and Corporate Secretary

    3100 Hanover Street

    Palo Alto, California, 94304

    (855) 698-8887

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Andrew Thorpe, Esq.

    Elena Vespoli, Esq.

    Gunderson Dettmer Stough Villeneuve

    Franklin & Hachigian, LLP

    One Bush Plaza

    Suite 1200

    San Francisco, California 94104

    Tel: (415) 978-9803

    Fax: (415) 978-9806

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 is being filed with the Securities and Exchange Commission (the “Commission”) for the purpose of registering an aggregate of an additional 4,795,700 shares of common stock of the Registrant issuable under the following employee benefit plans for which registration statements (File Nos. 333-227762, 333-236807, 333-253733, 333-263105, 333-270241, 333-277312 and 333-285168) of the Registrant on Form S-8 (the “Registration Statements”) are effective: (i) the Guardant Health, Inc. 2018 Incentive Award Plan which, as a result of the operation of an automatic annual increase provision therein, added 3,689,000 shares of common stock and (ii) the Guardant Health, Inc. 2018 Employee Stock Purchase Plan which, as a result of the operation of an automatic annual increase provision therein, added 1,106,700 shares of common stock.

    INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENTS ON

    FORM S-8

    Pursuant to General Instruction E of Form S-8, the contents of the Registration Statements on Form S-8 filed with the Commission on October 10, 2018 (File No.  333-227762), March 2, 2020 (File No. 333-236807), March 1, 2021 (File No. 333-253733), February  28, 2022 (File No. 333-263105), March  2, 2023 (File No. 333-270241), February  23, 2024 (File No. 333-277312) and February  24, 2025 (File No. 333-285168) are incorporated by reference herein.


    EXHIBIT INDEX

     

    Exhibit
    Number
            Incorporated by Reference   

    Filed

    Herewith

      

    Exhibit Description

      

    Form

      

    Date

      

    Exhibit

      

    File Number

    4.1    Amended and Restated Certificate of Incorporation.    8-K    10-9-18    3.1    001-38683   
    4.2    Amended and Restated Bylaws.    8-K    10-9-18    3.2    001-38683   
    5.1    Opinion of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP.                X
    10.1    2018 Incentive Award Plan.    S-8    10-10-18    99.2(a)    333-227762   
    10.2    Form of Stock Option Agreement under the 2018 Incentive Award Plan.    10-Q    8-7-24    10.2    001-38683   
    10.3    Form of Restricted Stock Award Agreement under the 2018 Incentive Award Plan.    S-1/A    9-21-18    10.9(b)    333-227206   
    10.4    Form of Restricted Stock Unit Award Agreement under the 2018 Incentive Award Plan.    10-Q    8-7-24    10.3    001-38683   
    10.5    Forms of Performance-Based Restricted Stock Unit Award Agreement under the 2018 Incentive Award Plan.    10-Q    8-7-24    10.4    001-38683   
    10.6    2018 Employee Stock Purchase Plan.    S-8    10-10-18    99.3    333-227762   
    10.7    First Amendment to 2018 Employee Stock Purchase Plan.    10-K    3-29-19    10.4(a)    001-38683   
    23.1    Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.                X
    23.2    Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP (included in Exhibit 5.1).                X
    24.1    Power of Attorney (incorporated by reference to the signature page hereto).                X
    107    Filing Fee Table.                X


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Palo Alto, California, on February 20, 2026.

     

    Guardant Health, Inc.
    By:  

    /s/ Michael Bell

      Michael Bell
      Chief Financial Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Helmy Eltoukhy, AmirAli Talasaz and Michael Bell and each of them, with full power of substitution and full power to act without the other, his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file this registration statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.


    Signature

      

    Title

     

    Date

    /s/ Helmy Eltoukhy

    Helmy Eltoukhy

      

    Co-Chief Executive Officer

    (Principal Executive Officer) and Chairman of the Board of Directors

      February 20, 2026

    /s/ AmirAli Talasaz

    AmirAli Talasaz

      

    Co-Chief Executive Officer

    (Principal Executive Officer) and Director

      February 20, 2026

    /s/ Michael Bell

    Michael Bell

      

    Chief Financial Officer

    (Principal Accounting Officer and Principal Financial Officer)

      February 20, 2026

    /s/ Ian Clark

    Ian Clark

       Director   February 20, 2026

    /s/ Alex M. Azar II

    Alex M. Azar II

       Director   February 20, 2026

    /s/ Vijaya Gadde

    Vijaya Gadde

       Director   February 20, 2026

    /s/ Meghan Joyce

    Meghan Joyce

       Director   February 20, 2026

    /s/ Steve Krognes

    Steve Krognes

       Director   February 20, 2026

    /s/ Manuel Hidalgo Medina

    Manuel Hidalgo Medina

       Director   February 20, 2026

    /s/ Roberto Mignone

    Roberto Mignone

       Director   February 20, 2026

    /s/ Myrtle Potter

       Director   February 20, 2026

    Myrtle Potter

        

    /s/ Musa Tariq

    Musa Tariq

       Director   February 20, 2026
    Get the next $GH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GH

    DatePrice TargetRatingAnalyst
    2/20/2026$125.00 → $135.00Buy
    Canaccord Genuity
    2/17/2026$120.00Outperform
    Robert W. Baird
    1/5/2026$105.00Outperform → In-line
    Evercore ISI
    12/2/2025$130.00Overweight
    Morgan Stanley
    9/25/2025$75.00Peer Perform → Outperform
    Wolfe Research
    9/22/2025$72.00Overweight
    Wells Fargo
    4/10/2025$55.00Outperform
    Mizuho
    1/23/2025$60.00Overweight
    Barclays
    More analyst ratings

    $GH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Krognes Steve E.

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    4/1/26 5:31:11 PM ET
    $GH
    Medical Specialities
    Health Care

    SEC Form 4 filed by Mignone Roberto

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    3/23/26 4:19:34 PM ET
    $GH
    Medical Specialities
    Health Care

    SEC Form 4 filed by Tariq Musa

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    3/19/26 5:16:17 PM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Guardant Health Inc.

    SCHEDULE 13G/A - Guardant Health, Inc. (0001576280) (Subject)

    3/27/26 9:35:03 AM ET
    $GH
    Medical Specialities
    Health Care

    SEC Form S-8 filed by Guardant Health Inc.

    S-8 - Guardant Health, Inc. (0001576280) (Filer)

    2/20/26 9:05:55 AM ET
    $GH
    Medical Specialities
    Health Care

    SEC Form 10-K filed by Guardant Health Inc.

    10-K - Guardant Health, Inc. (0001576280) (Filer)

    2/19/26 5:14:48 PM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Guardant Health's InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan

    This milestone underscores the power of Guardant Health's InfinityAI platform and real-world data to enable innovative evidence generation in rare biomarker-defined populations Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that real-world evidence generated from Guardant's InfinityAI contributed to the recent approval of ENHERTU® (trastuzumab deruxtecan), developed and commercialized by Daiichi Sankyo (TSE:4568) in Japan, for the treatment of patients with HER2-positive (HER2 [ERBB2] gene amplification or immunohistochemistry [IHC] 3+) advanced or recurrent solid cancers refractory or intolerant to standard treatments. This approval, granted by

    3/30/26 8:05:00 AM ET
    $GH
    Medical Specialities
    Health Care

    Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data

    Combination of high quality, variable-rich, curated EHR data with genomics enhances understanding of the patient journey and aids in therapy development SAN FRANCISCO, March 24, 2026 /PRNewswire/ -- Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), has announced a new partnership with leading precision oncology company Guardant Health Inc. (NASDAQ:GH) that will allow biopharmaceutical researchers to access the combined resources of Verana's regulatory-grade, therapeutic-specific EHR curated datasets from leading medical societies and academic and community medical centers and Guardant's clinicogenomic testi

    3/24/26 9:15:00 AM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026

    Guardant Reveal demonstrates expanded utility in identifying new, primary cancers during minimal residual disease (MRD) monitoring Studies show strong performance of Guardant360 Tissue in determining tissue of origin in diagnostically challenging settings Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the company and its research collaborators will present 28 abstracts, including 3 oral sessions, showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California taking place April 17 - 22, 2026. Key data that will be presen

    3/18/26 8:05:00 AM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity reiterated coverage on Guardant Health with a new price target

    Canaccord Genuity reiterated coverage of Guardant Health with a rating of Buy and set a new price target of $135.00 from $125.00 previously

    2/20/26 8:00:16 AM ET
    $GH
    Medical Specialities
    Health Care

    Robert W. Baird initiated coverage on Guardant Health with a new price target

    Robert W. Baird initiated coverage of Guardant Health with a rating of Outperform and set a new price target of $120.00

    2/17/26 8:18:22 AM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Guardant Health from Outperform to In-line and set a new price target of $105.00

    1/5/26 8:48:38 AM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Kalia Kumud bought $38,963 worth of shares (2,187 units at $17.82), increasing direct ownership by 21% to 12,722 units (SEC Form 4)

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    3/19/24 5:29:06 PM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 30, 2024 - FDA Roundup: July 30, 2024

    For Immediate Release: July 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA is announcing the fiscal year (FY) 2025 user fee rates for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) and accreditation and certification bodies interested in participating in the Accredited Third-Party C

    7/30/24 3:38:18 PM ET
    $GH
    Medical Specialities
    Health Care

    May 28, 2021 - FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy

    For Immediate Release: May 28, 2021 Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy. This is the first approved targeted therapy for tumors with any KRAS mutation, which accounts for ap

    5/28/21 1:05:48 PM ET
    $AMGN
    $GH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities

    May 21, 2021 - FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer

    For Immediate Release: May 21, 2021 Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The FDA also approved the Guardant360 CDx (Guardant Health Inc.) as a companion diagnostic for Ry

    5/21/21 12:50:51 PM ET
    $JNJ
    $GH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    $GH
    Leadership Updates

    Live Leadership Updates

    View All

    Alex M. Azar II Joins Guardant Health Board of Directors

    Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the appointment of Alex M. Azar II to its board of directors, effective immediately. As the 24th Secretary of the U.S. Department of Health and Human Services (HHS), Secretary Azar had oversight and management of agencies critical to all Americans' health care including the Centers for Medicare and Medicaid Services, the Food and Drug Administration, and the Center for Disease Control and Prevention. "We're honored to welcome Secretary Azar to Guardant's board," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "Secretary Azar has served at the senior-most levels of government as well as th

    9/15/25 4:07:00 PM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health Joins Forces With Dak Prescott's Faith Fight Finish Foundation and Feist-Weiller Cancer Center's Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities

    Foundation's grant to mobile cancer screening program in Louisiana allows individuals to be screened with Guardant's Shield™ blood test in their own community Mobile screening events to be held during Colorectal Cancer Awareness Month (March) throughout northern and central Louisiana Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced a collaboration with Dak Prescott's Faith Fight Finish Foundation and the mobile cancer screening program, Partners in Wellness, an initiative of LSU Health Shreveport and Ochsner LSU Health—Feist-Weiller Cancer Center, to increase colorectal cancer screening rates in northern and central Louisiana. This press release

    3/5/25 8:05:00 AM ET
    $GH
    Medical Specialities
    Health Care

    Roberto A. Mignone Joins Guardant Health Board of Directors

    Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Roberto A. Mignone to its board of directors, effective immediately. Mr. Mignone is the Founder and Managing Partner of Bridger Management LLC, an investment management firm founded in 2000 and specializing in long-term equity strategies. "We are fortunate to welcome Roberto Mignone to our board of directors, bringing his healthcare industry expertise, long-term vision, and business acumen to our company," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "We look forward to Mr. Mignone's perspective as we strengthen our product offerings across the continuum of care, and look

    10/24/24 5:05:00 PM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    Financials

    Live finance-specific insights

    View All

    Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

    Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, February 19, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer.

    1/29/26 4:05:00 PM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

    Revenue growth of 39% broadly driven by strong performance across Oncology, Screening, and Biopharma & Data Raises 2025 revenue guidance to $965 to $970 million, representing year-over-year growth of 31% Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights For the three-month period ended September 30, 2025, as compared to the same period of 2024: Reported total revenue of $265.2 million, an increase of 39%, driven by: Oncology revenue of $184.4 million, an increase of 31%, and approximately 74,000 oncology tests, an increase of 40% Screeni

    10/29/25 4:05:00 PM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025

    Expanded cohort reiterates strong adherence rate of over 90% for Shield blood-based colorectal cancer screening test Survey findings show eligible individuals prefer a blood test for colorectal cancer and lung cancer compared with traditional screening methods Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the company and its research collaborators will present data showing the critical role of blood-based testing in increasing cancer screening adherence at the American College of Gastroenterology (ACG) 2025 Annual Meeting in Phoenix, Arizona taking place Friday, October 24 – Wednesday, October 29, 2025. Building off findings from Guardant

    10/26/25 3:01:00 PM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Guardant Health Inc.

    SC 13G - Guardant Health, Inc. (0001576280) (Subject)

    11/13/24 7:34:17 PM ET
    $GH
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Guardant Health Inc.

    SC 13G - Guardant Health, Inc. (0001576280) (Subject)

    11/8/24 10:46:38 AM ET
    $GH
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Guardant Health Inc.

    SC 13G/A - Guardant Health, Inc. (0001576280) (Subject)

    7/5/24 10:32:48 AM ET
    $GH
    Medical Specialities
    Health Care